Global Colorectal Cancer Molecular Diagnostics Market Growth (Status and Outlook) 2025-2031

The global Colorectal Cancer Molecular Diagnostics market size is predicted to grow from US$ 755 million in 2025 to US$ 1718 million in 2031; it is expected to grow at a CAGR of 14.7% from 2025 to 2031.

Colorectal Cancer Molecular Diagnostics refers to the use of molecular techniques to detect specific genetic mutations, biomarkers, and molecular alterations associated with colorectal cancer. These diagnostics help in identifying cancer subtypes, predicting the patient's response to treatment, and assessing the risk of cancer recurrence. Methods used in molecular diagnostics include polymerase chain reaction (PCR), next-generation sequencing (NGS), and fluorescence in situ hybridization (FISH), among others. By providing personalized information about the tumor’s genetic profile, molecular diagnostics enable targeted therapies and improve the precision of treatment plans for colorectal cancer patients.

Colorectal Cancer Molecular Diagnostics Market Drivers:

Rising Prevalence of Colorectal Cancer: As colorectal cancer remains one of the most common cancers globally, the growing number of cases is a key driver for the molecular diagnostics market. Early detection and personalized treatment approaches are increasingly in demand.

Advancements in Molecular Diagnostics Technology: Innovations like next-generation sequencing (NGS), liquid biopsy, and biomarker discovery have improved the accuracy and efficiency of diagnostics, making them more accessible and appealing to healthcare providers and patients.

Personalized Medicine and Targeted Therapies: The shift toward personalized treatment in oncology, where therapies are tailored based on the patient’s genetic profile, is driving the adoption of molecular diagnostics to identify specific mutations and biomarkers in colorectal cancer.

Increasing Awareness and Screening Programs: Governments and health organizations are promoting regular colorectal cancer screenings, driving the demand for advanced diagnostic tests.

Colorectal Cancer Molecular Diagnostics Market Challenges:

High Costs and Reimbursement Issues: Advanced molecular diagnostics can be expensive, and the lack of consistent reimbursement policies across different regions limits their widespread adoption, particularly in low- and middle-income countries.

Complexity of Genetic Data Interpretation: As molecular diagnostics provide a vast amount of genetic data, interpreting these results requires specialized expertise. This can create a barrier in regions where access to highly skilled professionals is limited.

Regulatory Hurdles: Stringent regulations surrounding the approval and clinical use of molecular diagnostics can slow down market growth, especially when it comes to introducing new and innovative tests.

Limited Awareness in Developing Regions: While awareness of colorectal cancer and molecular diagnostics is growing in developed countries, many developing regions still face challenges related to lack of awareness and infrastructure for advanced diagnostic techniques.

Global core colorectal cancer molecular diagnostics players include Roche Diagnostics, Abbott and Thermo Fisher etc. The top 3 companies hold a share about 45%. North America is the largest market with a share about 43%, followed by Asia-Pacific and Europe.

LPI (LP Information)' newest research report, the “Colorectal Cancer Molecular Diagnostics Industry Forecast” looks at past sales and reviews total world Colorectal Cancer Molecular Diagnostics sales in 2024, providing a comprehensive analysis by region and market sector of projected Colorectal Cancer Molecular Diagnostics sales for 2025 through 2031. With Colorectal Cancer Molecular Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Colorectal Cancer Molecular Diagnostics industry.

This Insight Report provides a comprehensive analysis of the global Colorectal Cancer Molecular Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Colorectal Cancer Molecular Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Colorectal Cancer Molecular Diagnostics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Colorectal Cancer Molecular Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Colorectal Cancer Molecular Diagnostics.

This report presents a comprehensive overview, market shares, and growth opportunities of Colorectal Cancer Molecular Diagnostics market by product type, application, key players and key regions and countries.

Segmentation by Type:

Polymerase Chain Reaction PCR

Molecular Hybridization

Biochip

Others

Segmentation by Application:

Hospital

Third-Party Testing Agency

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Roche Diagnostics

Abbott

Thermo Fisher

Qiagen

Illumina

Biomerieux

Bio-Rad

Agilent

Daangene

Amoydx

Please note: The report will take approximately 2 business days to prepare and deliver.